May 15, 2017 / 11:24 AM / 3 months ago

BRIEF-Cancer Genetics partners with Ventana Medical Systems for market access to predictive biomarker test

May 15 (Reuters) - Cancer Genetics Inc

* Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to ensure market access to predictive biomarker test for new immuno-oncology (io) therapy for advanced bladder cancer

* Cancer Genetics - partnered with Ventana Medical Systems to enable rapid patient access to testing following FDA's approval of Roche's Ventana PD-l1 assay Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below